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Polycomb Group Proteins Are Key Regulators of
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Sivaprakasam Balasubramanian1
The Polycomb group (PcG) proteins are epigenetic
suppressors of gene expression that function through
modification of histones to change chromatin struc-
ture and modulate gene expression and cell behavior.
Recent studies show that PcG proteins are expressed
in epidermis, that their levels change during
differentiation and in disease states, and that PcG
expression is regulated by agents that influence cell
proliferation and survival. The results indicate that
PcG proteins regulate keratinocyte cell-cycle progres-
sion, apoptosis, senescence, and differentiation.
These proteins are expressed in progenitor cells, in
the basal layer, and in suprabasal keratinocytes, and
the level, timing, and distribution of expression
suggest that the PcG proteins have a central role
in maintaining the balance between cell survival
and death in multiple epidermal compartments.
Additional studies indicate an important role in skin
cancer progression.
Journal of Investigative Dermatology (2011) 131, 295–301;
doi:10.1038/jid.2010.318; published online 18 November 2010
INTRODUCTION
Polycomb group genes
The role of epigenetic regulation in modulating cell function
is an area of intense interest. The Polycomb group (PcG)
genes encode a family of evolutionarily conserved epigenetic
regulators that were discovered in Drosophila as repressors of
the genes that control body segmentation. In mammalian
systems PcG proteins regulate genes involved in develop-
ment, differentiation, and survival through epigenetic
(for example, chromatin modification) mechanisms (Orlando,
2003; Valk-Lingbeek et al., 2004). Gene silencing by PcG
proteins involves the sequential action of two polycomb
repressor complexes—PRC2 and PRC1. The PRC2 protein
complex includes four core proteins—Ezh2, Suz12, eed, and
RBAP48 (Figure 1). The catalytic subunit of this complex is
Ezh2, a methyltransferase that methylates H3-K27 through its
SET domain-encoded catalytic site (Simon and Lange, 2008).
The complex contains three noncatalytic subunits, including
Suz12, eed (embryonic ectoderm development), and RBAP48
(retinoblastoma-binding protein p48). Suz12 and eed are
required for optimal Ezh2 histone methyltransferase activity.
The complex is not invariant and alternative subunits can be
substituted including Ezh1 for Ezh2, RBAP46 for RBAP48,
and there are several eed variants derived from a common
gene (Simon and Kingston, 2009). Interaction of Suz12 and
eed with Ezh2 results in a 1,000-fold increase in Ezh2
catalytic activity, showing that the full complex is required
for optimal trimethylated histone H3 lysine K27 (H3K27me3)
formation (Cao and Zhang, 2004; Pasini et al., 2004).
The PRC1 protein complex includes a core of four
proteins including Ring1B, Bmi-1, PH1, and CBX (Simon
and Kingston, 2009). The catalytic subunit of this complex,
Ring1B, ubiquitinylates H2A-K119 and is optimally active in
association with Bmi-1 (Li et al., 2006). An important role of
the CBX protein is interaction with H3K27me3 to anchor the
PRC1 complex to chromatin (Hatano et al., 2010). The PRC1
complex is also not invariant and proteins can be substituted
including Ring1 for Ring1B, MEL18, or NSPC1 for Bmi-1,
CBX2, 6, 7, or 8 for CBX, and PH2 for PH1 (Orlando, 2003;
Levine et al., 2004; Sparmann and van Lohuizen, 2006;
Simon and Kingston, 2009). PRC1 has been proposed
to ubiquitinylate H2A-K119 as part of the process leading
to a closed chromatin state. However, recent findings suggest
that a second complex, BCOR, which consists of Ring1B,
Ring1, NSPC1, FBXL10, and BCOR, may also have an
important role in H2A-K119 ubiquitinylation (Simon and
Lange, 2008; Simon and Kingston, 2009).
Modification of chromatin by PRC2 and PCR1 is a
coordinated sequential process. It is initiated by interaction
of PRC2 with chromatin through a mechanism that is not well
understood. Polycomb response elements have been identi-
fied in Drosophila chromatin. Polycomb response elements
serve as DNA binding sites for ‘‘recruiter proteins’’, including
PHO and PHOL, to recruit the PRC2 complex to chromatin
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(Brown et al., 1998, 2003; Mihaly et al., 1998). Polycomb
response elements have not been well described in mamma-
lian cells, but YY1 and Oct4 have been proposed to serve as
recruiter proteins in specific contexts (Caretti et al., 2004;
Endoh et al., 2008), and noncoding RNA may also function as
part of the recruiting complex (Rinn et al., 2007; Pandey
et al., 2008).
The first step in polycomb complex-mediated chromatin
modification is performed by PRC2. The Ezh2 protein of the
PRC2 complex catalyzes trimethylation of Lys27 of histone
H3 (H3K27me3). In the next step, the CBX protein of the
PRC1 complex binds to H3K27me3 to anchor the PRC1
complex at this site and the PRC1 Ring1B protein catalyzes
ubiquitinylation of histone H2A at lysine K119 (Figure 2;
Fischle et al., 2003; Cao et al., 2005). These events lead to
chromatin compaction-mediated suppression of transcrip-
tion. The mechanism of transcription repression is not
well defined, but the chromatin compaction may block
transcription factor–DNA interaction or inhibit transcript
elongation. Recent findings suggest that inhibition of tran-
script elongation may be a key mechanism (Stock et al.,
2007; Zhou et al., 2008). The combination of PRC2/PRC1
action results in the stable suppression of gene expression and
the resulting gene silencing is associated with increased cell
proliferation/survival and decreased senescence and differ-
entiation (Jacobs and van Lohuizen, 2002; Orlando, 2003).
PcG proteins are important in maintaining stem cell
survival during development (Lessard and Sauvageau, 2003;
Molofsky et al., 2003; Iwama et al., 2004), but they also
function in adult organisms. For example, knockout mice
lacking the PRC1 complex Bmi-1 protein lose stem cells after
birth (Lessard and Sauvageau, 2003; Molofsky et al., 2003;
Leung et al., 2004), Bmi-1-deficient fibroblasts show slowed
proliferation and enhanced senescence (Jacobs et al., 1999b)
and cells with elevated Bmi-1 expression show increased cell
proliferation (Lessard and Sauvageau, 2003; Yu et al., 2007).
Bmi-1 is also important in disease, as it is overexpressed in
many tumor types (Vonlanthen et al., 2001; Breuer et al.,
2004; Kim et al., 2004a, b) and collaborates with various
oncogenes to enhance cell proliferation and survival (Haupt
et al., 1993; Jacobs et al., 1999a, b; Dimri et al., 2002; Datta
et al., 2007; Haga et al., 2007; Brunner et al., 2008).
The prototypic mode of Bmi-1 action is suppression of
gene expression. The Ink4a/Arf locus was one of the first
targets identified (Bracken et al., 2007). This locus encodes
two tumor suppressor genes called p16Ink4a and p14Arf (p19Arf
in mouse) that are transcribed in independent reading frames
(Jacobs et al., 1999b). This locus has a key role in control of
cell-cycle progression. p16ink4a inhibits the kinase activity
of the cyclin D-dependent kinases, Cdk4 and Cdk6, and
prevents their association with cyclins. This ultimately leads
to reduced pRB phosphorylation and reduced cell-cycle
progression through G1 (Serrano et al., 1993). p16
ink4a levels
are normally reduced under conditions of cell-cycle progres-
sion. Consistent with this role, cells in p16Ink4a knockout
mice are more susceptible to malignant progression
(Krimpenfort et al., 2001; Sharpless et al., 2001). p14Arf
promotes cell-cycle arrest by interacting with MDM2 and
reducing its ability to target p53 for degradation. This also
ultimately leads to cell-cycle arrest (Weber et al., 1999; Lowe
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Figure 1. Polycomb complexes. The PRC2 complex consists of four core
proteins including RBAP48, SUZ12, EZH2, and EED. EZH2 is the
methyltransferase responsible for methylation of lysine 27 of histone H3, and
this methylation activity resides in the SET domain. Interaction with other
proteins in the complex is required for EZH2 activity. PHF1 is a polycomb
protein that is not part of the core complex, but functions to increase EZH2
activity and is also involved in PRC2 complex interaction with chromatin.
The PRC1 complex comprises four core proteins including RING1B, CBX,
Bmi-1, and PH1. RING1B is an E3 ubiquitin ligase that specifically
ubiquitinylates lysine 119 of histone H2A. Bmi-1 interacts directly with
RING1B to enhance Ring1B ubiquitin ligase activity. CBX encodes the
domain (chromodomain, CD) responsible for anchoring the PRC1 complex
to methylated lysine 27 of histone H3.
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Figure 2. Simplified description of PcG regulation of transcription. The
PRC2 complex is recruited to chromatin, and the Ezh2 protein of this
complex, a histone methyltransferase, catalyzes formation of H3K27me3
through its SET catalytic site. H3K27me3 then functions as a binding site for
the CBX protein of the PRC1 complex. CBX encodes a chromodomain site
that has a high affinity for H3K27me3. The interaction of CBX with
H3K27me3 anchors the PRC1 complex to chromatin, and the RING1B
subunit of the complex, an E3 ubiquitin ligase, catalyzes formation of H2A-
K199-ub. Ultimately these events lead to chromatin folding and compaction
and cessation of transcription. The dashed line indicates binding interaction
and the solid lines indicate covalent modifications.
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and Sherr, 2003). Thus, in the presence of Bmi-1, p16Ink4a
and p14Arf levels are reduced thereby permitting the cells to
proliferate. As noted below, the Ink4a/Arf locus is an
important target gene in keratinocytes, but other target genes
have also been identified.
PcG genes in epidermis
Recent studies have begun to focus on the role of the PcG
gene products in epidermis, with a particular emphasis on
Bmi-1. The epidermis is a multilayered tissue that includes
three major functional compartments—undifferentiated cells
that retain proliferative potential, differentiating cells that are
viable but not able to proliferate, and terminally differentiated
dead cells. Maintaining the relative size of these compart-
ments requires that the cell proliferation rate in the basal
layer, the tendency of cells to survive versus differentiate in
the suprabasal layers, and terminal cell death in the cornified
layer be coordinately controlled and balanced (Eckert et al.,
1997). Recent studies suggest that the PcG gene products
regulate these processes. As noted above, Bmi-1 is a
component of the PRC1 PcG complex that functions in the
nucleus to modify chromatin and suppress gene expression
(Cohen et al., 1996; Aoto et al., 2008). Indeed, Bmi-1
is localized in the nucleus of proliferating keratinocytes in
culture (Silva et al., 2006; Lee et al., 2008) and has been
detected in the cytoplasm of quiescent keratinocytes
(Silva et al., 2006). These findings are consistent with the
fact that Bmi-1 has a nuclear localization signal and that
inactive Bmi-1 can shuttle to the cytoplasm (Cohen et al.,
1996). Bmi-1 was originally characterized as a stem cell
maintenance protein that is required for efficient renewal of
hematopoietic stem cells (Jacobs et al., 1999a; Molofsky
et al., 2003; Park et al., 2003), and leukemic and neuronal
stem cells (Lessard and Sauvageau, 2003; Molofsky et al.,
2003). However, Bmi-1 does not appear to function
exclusively as a stem cell regulator in epidermis. If this were
the case, one would expect expression to be restricted to
epidermal stem cells compartments. However, the available
evidence suggests that Bmi-1 is expressed in multiple
epidermal layers, both basal and suprabasal, and is not
strictly confined to stem cells (Ressler et al., 2006; Reinisch
et al., 2007; Balasubramanian et al., 2008; Lee et al., 2008;
Shaw and Martin, 2009). These findings suggest that Bmi-1 is
likely to function in multiple epidermal cell layers.
Bmi-1: role in cell survival, proliferation, and senescence
Recent studies have investigated the role of Bmi-1 in
regulating keratinocyte senescence. Senescence is a process
whereby aging cells gradually lose proliferative potential
(Barrandon and Green, 1987). Senescence has the physiolo-
gical role of limiting the long-term survival of self-renewing
cells during aging. A hallmark of senescence is increased
expression of products of the Ink4a/Arf locus, p16Ink4a and
p14Arf (p19Arf in mouse cells) (Krishnamurthy et al., 2004).
Dellambra and co-workers, using the holoclone/meraclone/
paraclone clonogenic assay system (Barrandon and Green,
1987), have measured the expression of Bmi-1 as keratino-
cytes undergo progressive restriction in replicative potential.
These studies reveal that Bmi-1 level is high in holoclones
(cells with high proliferative potential) and low in paraclones
(cells with limited potential) and that there is an inverse
relationship between p16Ink4a level and Bmi-1 content. Thus,
cells that have high proliferative potential have high Bmi-1
and low p16Ink4a (Silva et al., 2006; Cordisco et al., 2010).
This relationship is also observed in aging epidermis, as Bmi-1
levels are high in keratinocytes isolated from young
individuals and lower in cells isolated from older individuals
(Ressler et al., 2006; Cordisco et al., 2010). Bmi-1 levels are
also reduced in keratinocytes from young xeroderma
pigmentosum group c, trichothiodystrophy, and progeria
patients as compared to keratinocytes isolated from healthy
young individuals (Cordisco et al., 2010). In addition,
keratinocytes derived from photo-aged epidermis have lower
Bmi-1 level than keratinocytes collected from nonexposed
epidermis of the same patient (Cordisco et al., 2010).
Treatment with trichostatin A results in replicative senes-
cence and this is associated with reduced Bmi-1 level
(Cordisco et al., 2010). These studies imply that Bmi-1
has a role in controlling keratinocyte senescence via
regulation of the Ink4a/Arf locus.
Keratinocyte survival and proliferation are also influenced
by Bmi-1. Treatment with chemopreventive agent or kerati-
nocyte differentiating/apoptosis-inducing agent reduces
Bmi-1 expression and the expression of other PcG proteins,
and this is associated with reduced survival of normal and
transformed keratinocytes (Lee et al., 2008; Balasubramanian
et al., 2010). Bmi-1 overexpression in keratinocytes enhances
cell number which is associated with increased expression of
cdk2 (Lee et al., 2008), Bmi-1 expression extends the
replicative life span of keratinocyte-like cells derived from
human embryonic stem cells (Dabelsteen et al., 2009) and
Bmi-1 siRNA reduces proliferation of the SCC-13 skin cancer
cells (Balasubramanian et al., 2010). In this context, Bmi-1
may serve as a prosurvival protein (Lee et al., 2008;
Balasubramanian et al., 2010).
Agents that regulate Bmi-1 level in keratinocytes
Given that Bmi-1 regulates keratinocyte survival, it is perhaps
not surprising that various extrinsic and intrinsic processes
such as cell aging (Silva et al., 2006) and treatment
with growth regulatory agents may influence Bmi-1 level
(Balasubramanian et al., 2010; Cordisco et al., 2010).
Treating with agents that alter keratinocyte survival mod-
ulates Bmi-1 level. Hydrogen peroxide treatment reduces
Bmi-1 level (Cordisco et al., 2010) as does expression of
Ha-Ras(G12V), a constitutively active form of Ha-ras
(Cordisco et al., 2010). Potential therapeutic agents also
influence Bmi-1 expression. Treatment of keratinocytes with
()-epigallocatechin-3-gallate (EGCG), which is the major
bioactive chemopreventive agent in green tea (Ahmad and
Mukhtar, 1999), reduces Bmi-1 level in keratinocytes (Lee
et al., 2008; Balasubramanian et al., 2010). This reduction in
Bmi-1 level is associated with reduced cell survival and
proliferation, and reduced levels of cdk1, cdk2, cdk4, cdk6,
cyclin D1, and cyclin E. In addition to reducing Bmi-1 level,
EGCG treatment also reduces expression of the PRC2
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complex proteins, Ezh2 and Suz12, and reduces histone H3
lysine K27 trimethylation (H3K27me3; Balasubramanian
et al., 2010). Ezh2, a component of the PRC2 complex, is
the methyltransferase that specifically methylates H3-K27 to
form H3K27me3 (Kirmizis et al., 2004; Wang et al., 2004;
Kuzmichev et al., 2005). These findings indicate that
treatment with EGCG reduces function of both the PRC2
and PRC1 complexes. An interesting finding is that over-
expression of Bmi-1, a PRC1 complex protein, is associated
with increased expression of Ezh2, a PRC2 complex protein,
suggesting that Bmi-1 somehow functions to maintain
expression of the enzyme that prepares its chromatin
(H3K27me3) binding site (Balasubramanian et al., 2010).
Impact of Bmi-1 on apoptosis
It has been appreciated for several years that Bmi-1 functions
to enhance cell survival by regulating cell-cycle-related
events. However, less has been studied regarding the impact
of Bmi-1 on apoptosis. Recent studies show that challenging
keratinocytes with okadaic acid or EGCG results in activation
of apoptosis as measured by accumulation of sub-G1 cells
and accumulation of cleaved caspases 3 and 9 and PARP
(Lee et al., 2008; Balasubramanian et al., 2010). Forced
expression of Bmi-1 reverses the okadaic acid/EGCG-
associated activation of apoptosis (Lee et al., 2008;
Balasubramanian et al., 2010). This finding indicates that
Bmi-1 influences a broad range of responses in keratinocytes
and the effects cannot be solely explained by Bmi-1-
dependent enhancement of cell proliferation or inhibition
of senescence. The mechanism of regulation of apoptosis by
Bmi-1 is likely to be indirect but has not been investigated.
Other PcG proteins in epidermis
Other PcG proteins have also been studied in epidermis
including the PRC2 complex components, Ezh2 and Suz12.
Ezh2 expression is inversely correlated with the differentia-
tion status of keratinocytes (Ezhkova et al., 2009). Ezhkova
et al. observed high-level Ezh2 expression in keratinocytes
maintained in low calcium medium and reduced levels in
cells differentiated by treatment with high calcium. More-
over, strong Ezh2 expression is observed in epidermal
progenitor cells and the level gradually declines as the cells
differentiate. It is interesting that Ezh2 levels, although
reduced, are still detected in suprabasal epidermal layers
(Ezhkova et al., 2009). These findings suggest that Ezh2 may
participate in regulating the survival/differentiation balance
in multiple epidermal compartments. Chromatin immuno-
precipitation analysis reveals extensive H3K27me3 modifica-
tion of chromatin in differentiation marker genes in basal
progenitor cells, which is associated with gene silencing.
Thus, Ezh2 appears to have a role in suppressing differentia-
tion-associated gene expression in basal epidermis (Ezhkova
et al., 2009). In addition, loss of Ezh2 from the promoter
region of differentiation-associated genes is inversely asso-
ciated with accumulation of AP1 transcription factors at these
sites and gene activation (Ezhkova et al., 2009). Additional
studies show increased Ezh2, Suz12 level, and H3K27me3
formation in immortalized/transformed skin cancer cell lines
including A431, SCC-13, and HaCaT cells (Balasubramanian
et al., 2010), and that Ezh2 knockdown reduces H3K27me3
formation and this is associated with reduced SCC-13 cell
proliferation and survival. Ezh2 is an example of a PRC2
protein that is overexpressed in tumors (Varambally et al.,
2002; Raaphorst et al., 2003; Raman et al., 2005; Sudo et al.,
2005; Saramaki et al., 2006).
In addition to PcG proteins, which are involved in
H3K27me3 formation, a class of demethylases have recently
been described that specifically erase this mark (Lan et al.,
2008; Nottke et al., 2009; Mosammaparast and Shi, 2010).
Thus, the PcG protein Ezh2 promotes H3K27me3 formation,
whereas the Jumanji C domain-containing H3K27me3-
specific demethylases, UTX and JMJD3, remove this mark.
A recent study by Khavari and colleagues show that
H3K27me3 marks the promoter of many genes that are
expressed during differentiation and that loss of this mark is
observed when these genes are expressed during calcium-
dependent differentiation (Sen et al., 2008). The authors
suggest that epigenetic derepression by JMJD3 enhances
keratinocyte differentiation. These findings again emphasize
the importance of epigenetic modification in regulating the
balance between keratinocyte survival and differentiation.
PcG proteins in skin cancer
Several studies have examined the role of PcG proteins in the
pathogenesis of skin cancer. Bmi-1 overexpression in HaCaT
cells causes malignant transformation as measured by colony
formation in soft agar and tumor formation in severe
combined immunodeficient mice (Wang et al., 2009).
Moreover, Bmi-1 expression is observed at elevated levels
in squamous cell carcinoma (SCC) tumors (Reinisch et al.,
2007; Balasubramanian et al., 2010). Cultured skin cancer
cells express elevated Bmi-1, Suz12, and Ezh2 levels
as compared to normal cells and this is associated with
increased H3K27me3 (Balasubramanian et al., 2010).
Chemopreventive agents suppress proliferation of tumor cells
and this is associated with reduced expression of cdk1, cdk2,
cdk4, and cyclins D1, E, and A. The level of the cyclin-
dependent kinase (cdk) inhibitors p21 and p27 is increased
in these cells (Balasubramanian et al., 2010). As noted
above, these chemopreventive agent-associated changes are
reversed by forced overexpression of Bmi-1. Chemopreven-
tive agent treatment also activates apoptosis in skin cancer
cells as evidenced by increased caspase and PARP cleavage
and appearance of sub-G1 cells. It is interesting that these
effects are also reversed by forced Bmi-1 expression
(Balasubramanian et al., 2010). A potentially meaningful
observation is that forced Bmi-1 expression restores Ezh2
levels in EGCG-treated SCC-13 cells, suggesting that feed-
back regulation functions to assure an appropriate balance of
PRC1 and PRC2 complex proteins in cells (Balasubramanian
et al., 2010). This may be important as Bmi-1 is not likely to
be functional in the absence of Ezh2 and Bmi-1 chromatin
binding site is synthesized by Ezh2. Bmi-1 also provides
protection when normal keratinocytes are challenged
with the differentiation/apoptosis promoting agent, okadaic
acid, by inhibiting okadaic acid-dependent apoptosis
298 Journal of Investigative Dermatology (2011), Volume 131
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(Lee et al., 2008). It is also important to note that PcG protein
function is also altered in other skin cancer types. For
example, PcG protein levels are elevated in basal cell
carcinoma (Reinisch et al., 2007) and melanoma (Bachmann
et al., 2006; Mihic-Probst et al., 2007).
Processes in wound healing are related to processes that
control development and abnormal regulation observed in
cancer cells. It is interesting that three major components of
the PRC2 complex, eed, Ezh2, and Suz12, are reduced in
epidermis during wound healing (Shaw and Martin, 2009).
Reexpression of these proteins is observed approximately
10 cells back from the wound edge, and it is proposed that
PcG proteins may be involved in silencing the repair genes
after completion of wound healing. The loss of these PcG
proteins, as expected, is associated with reduced levels of
H3K27me3 in the healing epidermis (Shaw and Martin,
2009). Epidermal growth factor receptor and the c-myc genes
are markers of the wound healing process. Using a cell
culture model, Shaw and Martin (2009) showed that forced
expression of eed resulted in reduced epidermal growth
factor receptor and c-myc gene expression. These results
appear to conflict with the idea that PcG protein expression
correlates with enhanced cell survival and increased expres-
sion of survival genes. These findings, however, highlight
the potential complexity of this regulation, and suggest that
the role of the PcG proteins may be context dependent.
CONCLUSION
The findings described above support several conclusions
regarding the function of PcG proteins in epidermis. First,
expression of Bmi-1 and other PcG proteins is not strictly
confined to stem cells in normal epidermis or in cancer cells.
A gradient appears to exist such that basal cells express more
Bmi-1 (for example) than suprabasal cells; however, expres-
sion is observed in a wide range of cells in the progenitor,
basal, and suprabasal layers. This suggests that although Bmi-1
expression, and the expression of other PcG proteins,
correlates inversely with survival potential, they are not
strictly stem-cell-specific proteins (Lee et al., 2008; Ezhkova
et al., 2009; Cordisco et al., 2010). Second, Bmi-1 and
other PcG proteins enhance expression of pro-proliferation
cell-cycle regulatory proteins and suppress differentiation and
apoptosis (Silva et al., 2006; Lee et al., 2008; Ezhkova et al.,
2009). Moreover, in general, loss of the H3K27me3 mark is
associated with expression of differentiation marker
genes and reduced cell proliferation/survival. Third, Bmi-1
and other PcG proteins are expressed at higher levels in
tumors, both SCC (Reinisch et al., 2007; Balasubramanian
et al., 2010), basal cell carcinoma (Reinisch et al., 2007) and
melanoma (Bachmann et al., 2006; Mihic-Probst et al.,
2007), although the Bmi-1 finding is somewhat controversial
for melanoma, as one report describes reduced expression
with clinical progression in malignant melanoma (Bachmann
et al., 2008). Moreover, forced Bmi-1 expression in HaCaT
cells causes transformation (Wang et al., 2009). This suggests
that overexpression of these proteins may be one mechanism
whereby tumor cells escape death through a mechanism that
involves modulation of cell cycle and apoptotic processes
(Lee et al., 2008; Balasubramanian et al., 2010). Thus,
although it is possible that Bmi-1 could be restricted to
maintaining survival of tumor stem cells, the ubiquitous
distribution of Bmi-1 in skin tumor cells suggests a broader
role in skin cancer (Balasubramanian et al., 2008). Fourth,
PcG protein expression declines in aging epidermis, showing
that loss of PcG protein expression is associated with
keratinocyte senescence both in vivo and in cell culture
models (Ressler et al., 2006; Cordisco et al., 2010). Fifth,
Bmi-1 and other PcG proteins are likely important targets for
cancer prevention, as the level of these proteins is reduced in
cells treated with chemopreventive agent and the action
of chemopreventive agent is antagonized by overexpression
of these proteins (Balasubramanian et al., 2008, 2010).
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